口腔鳞癌新辅助化疗前后多药耐药相关蛋白的表达及临床疗效分析

Expression Level and Clinical Efficacy of Multidrug Resistant Proteins before and after Neoadjuvant Chemotherapy in OSCC

目的:观察口腔鳞癌患者新辅助化疗疗效与5年生存率的关系,并探讨P-gp、MRP1、GST-π与新辅助化疗疗效的关系。方法:1)收集南昌大学第一附属医院诊治的口腔鳞癌石蜡标本77例(有效组50例,无效组27例),随访5年生存时间,Envision法检测P-gp、MRP1、GST-π表达水平;2)收集本单位口腔鳞癌新鲜标本33例(有效组18例,无效组15例),qPCR、WesternBlot法检测P-gp、MRP1、GST-π表达水平。结果:1)KaplanMeier显示:有效组5年生存率高于无效组(P<0.05)。2)Envision、qPCR、WesternBlot显示:无效组化疗后Pgp、MRP1表达上升量较有效组有显著差异(P<0.05),而GST-π表达上升量无显著差异(P>0.05)。结论:口腔鳞癌新辅助化疗有效组5年生存率明显高于无效组;化疗疗效与P-gp、MRP1表达相关,表达上升量越高,疗效越差。

Objective： To observe the relationship between therapeutic efficacy and 5--year survival rate of OSCC patients after neoadjuvant chemotherapy, and to explore the relationship between P--gp, MRP1, or GST n and therapeutic efficacy after neoadjuvant chemotherapy. Methods： Seventy--seven OSCC paraffin specimens （50 valids and 27 invalids） were collected from the First Affiliated Hospital of Nanchang University. The 5- year survival time was followed up. Envision assay was used to determine the expression level of P--gp, MRP1, and GST n. Thirty--three OSCC fresh specimens （18 valids and 15 invalids） were collected, qPCR and Western Blot assay were used to detect the expression level of P gp, MRP1, and GST--n. Results： The Kaplan--Meier assay showed that 5 year survival rate of valid group was better than that of invalid group （P〈0. 05）. The results of Envision, qPCR, and Western Blot showed that the increased expression levels of P--gp and MRP1 in valid group were signif- icantly higher than those in invalid group （P〈0.05）. Conclusion= The 5--year survival rate of valid group was ob viously higher than that of invalid group after the neoadjuvant chemotherapy. The expression levels of P--gp and MRP1 were related to therapeutic efficacy. The higher expression levels of P gp and MRP1 were followed by the inferior therapeutic efficacy.